From LIMS to Autonomous AI Scientists — Kevin Cramer (Sigmatic Sciences) | Tech & Drugs

Kevin Cramer has spent over two decades in lab informatics. He founded Sapio Sciences, unifying LIMS and electronic lab notebooks into a single R&D platform, and now leads Sigmatic Sciences, building autonomous, agentic AI systems and Scout — an AI scientist built for the wet lab.In this episode of Tech & Drugs, Kevin and Thibault Géoui get into why pharma was great at science but treated software as an afterthought, why "how do I get data OUT of the system" was the question nobody asked, and what a post-ELN world actually looks like. They dig into agentic pipelines and why accuracy compounds across agents, the lab-in-the-loop DMTA cycle, "agentic burnout" when you're the gatekeeper for 300 agents, the difference between LLMs and specialized scientific agents, and why the real bottleneck is trust and change management rather than technology. Kevin closes with the bet he'd stake his career on.A conversation about where in silico discovery is heading — and what has to change for scientists to actually use it.━━━━━━━━━━━━━━━━━━━━━━━━━━━━━CONNECT WITH KEVIN CRAMERLinkedIn: https://www.linkedin.com/in/kevincramerveloxity/Sigmatic Sciences: https://www.sigmaticsciences.com/Sapio Sciences: https://www.sapiosciences.com/━━━━━━━━━━━━━━━━━━━━━━━━━━━━━CONNECT WITH THIBAULT GÉOUILinkedIn: https://www.linkedin.com/in/thibaultgeoui/━━━━━━━━━━━━━━━━━━━━━━━━━━━━━Tech & Drugs explores how AI, data, and technology are reshaping pharma and life sciences R&D — in conversation with the people building it.Subscribe for new episodes.#TechAndDrugs #AIinPharma #DrugDiscovery #AgenticAI #LabInformatics #LifeSciences #AIScientist